[HTML] frontiersin.org

[HTML][HTML] Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis

J Li, Z Zhang, X Wu, J Zhou, D Meng… - Frontiers in …, 2021 - frontiersin.org
Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-
tumor necrosis factor (anti-TNF) medicines that have been approved for use in …
被引用次数：59 相关文章

Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

J Li, Z Zhang, X Wu, J Zhou… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-
tumor necrosis factor (anti-TNF) medicines that have been approved for use in …

Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis.

J Li, Z Zhang, X Wu, J Zhou, D Meng… - Frontiers in …, 2021 - europepmc.org
Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-
tumor necrosis factor (anti-TNF) medicines that have been approved for use in …
[HTML] nih.gov

[HTML][HTML] Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

J Li, Z Zhang, X Wu, J Zhou, D Meng… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-
tumor necrosis factor (anti-TNF) medicines that have been approved for use in …